HCC827 Cells
| Unit |
3 x 10^6 cells/ml |
|---|---|
| Cell Type |
Tumor Cells |
| Tissue Type |
Lung cancer cell lines |
| Organism |
Human |
| Donor History |
Lung adenocarcinoma |
| Growth Properties |
Adherent |
| Growth Conditions |
Culture medium: RPMI 1640 ,w: 2.0 mM stable Glutamine ,w: 2.0 g/L NaHCO3 (Cytion article number 820700a). Supplements: Supplement the medium with 10% FBS. Dissociation reagent: Accutase. Freeze medium: As a cryopreservation medium ,we use complete growth medium (including FBS) + 10% DMSO for adequate post-thaw viability ,or CM-1 (Cytion catalog number 800100) ,which includes optimized osmoprotectants and metabolic stabilizers to enhance recovery and reduce cryo-induced stress. Incubation atmosphere: 37°C ,5% CO2 ,humidified atmosphere. |
| Immortalization Method | |
| Full Information |
HCC827 is a human non-small cell lung cancer cell line derived from the lung adenocarcinoma of a middle-aged female patient. These cells exhibit an epithelial morphology and are often used in research related to the epidermal growth factor receptor (EGFR). HCC827 cells are particularly noted for their sensitivity to tyrosine kinase inhibitors (TKIs), specifically those targeting EGFR mutations. This characteristic makes them a valuable model for studying the molecular mechanisms of lung cancer responsiveness to EGFR inhibitors, as well as for testing the efficacy of new therapeutic agents targeting EGFR-dependent pathways.
The cell line is also used to explore the mechanisms of acquired resistance to targeted therapies, which is a significant challenge in the treatment of lung cancer. Studies utilizing HCC827 cells have contributed to a better understanding of the genetic and epigenetic alterations that confer resistance to EGFR inhibitors. These findings have implications for the development of strategies to overcome resistance and improve treatment outcomes in lung cancer patients. Furthermore, the HCC827 cell line serves as a tool for investigating the broader cellular and molecular landscape of lung adenocarcinoma, including studies on cell signaling, tumor microenvironment, and cancer metastasis.
Společnost Cytion vznikla v roce 2004 v německém Heidelbergu s jasným vědeckým posláním: dodávat ověřené lidské a zvířecí buněčné linie bez kontaminace, připravené za přísně kontrolovaných laboratorních podmínek.
Postupně se vypracovala ve spolehlivou buněčnou banku, která slouží akademickým laboratořím, biotechnologickým firmám i farmaceutickým výzkumným týmům po celém světě. Klade přitom důraz na reprodukovatelnost výsledků, přísnou kontrolu kvality a dlouhodobá partnerství.
Mikrobiologické aplikace
NGS
Rapid testy
PCR plasty
Třepačky
Suché lázně
Fluorometry
Buněčné kultury
PCR, qPCR, RT
Detekce Mycoplasmat
Reverzní transkripce
Alergie
Intolerance
Elisa
Imunologické analyzátory
Veterinární imunologie
Alergie u zvířat
Intolerance u zvířat
Čtečky identifikačních čipů
Termočipy
Biochemie
Imunoanalýza

